Axcella Health Inc.
AXLADelisted Feb 15, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001633070
Axcella Health Inc. was delisted on Feb 15, 2024; its insiders filed their last Form 4 on Mar 3, 2023; 15 institutions reported holding it in 13F filings for Q3 2023, worth $17.1M in total; no superinvestor held it.
Q4 2023 vs. Q3 2023
How the institutions holding Axcella Health Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 15 | 1 | −14 |
| Shares | 1.64M | 80 | −1.64M (−100.0%) |
| Value | $17.1M | $32 | −$17.1M (−100.0%) |
New holders (0)
Institutions that held Axcella Health Inc. at the end of Q4 2023 but not at the end of Q3 2023.
None.
Sold out (14)
Institutions that held Axcella Health Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Flagship Pioneering Inc. | 1,170,059 | $12.2M |
| HarbourVest Partners LLC | 248,317 | $2.59M |
| Schonfeld Strategic Advisors LLC | 100,600 | $1.05M |
| FMR LLC | 66,455 | $693.8K |
| Vanguard Group Inc | 32,034 | $334.4K |
| Geode Capital Management, LLC | 11,022 | $115.1K |
| BlackRock Inc. | 9,903 | $103.4K |
| Tower Research Capital LLC (TRC) | 1,225 | $12.8K |
| JPMorgan Chase & Co | 1,073 | $11.2K |
| Morgan Stanley | 1,004 | $10.5K |
| Royal Bank of Canada | 240 | $3.00K |
| UBS Group AG | 106 | $1.11K |
| Bank of America Corp | 26 | $271 |
| Wells Fargo & Company | 8 | $84 |